Alerta

OXIDATION-RESPONSIVE CATIONIC WATER-SOLUBLE PILLARARENE, AND PREPARATION METHOD AND USE

Resumen de: EP4818181A1

Disclosed are an oxidation-responsive water-soluble cationic pillararene, and a preparation method and application thereof, the oxidation-responsive water-soluble cationic pillararene is a cyclic small-molecule nucleic acid vector, and is obtained by quaternization reaction of 4-methylborate and tertiary amine-modified pillararene. According to the invention, a delivery vector with a high positive charge density is obtained through small molecule synthesis, the delivery vector is capable of being tightly combined with negatively charged nucleic acid substances to form a nano-composite, and after the nano-composite enters cells, vector positive charges fall off to release the nucleic acid substances in an oxidation environment, and nucleic acid information is efficiently expressed. The delivery vector has the characteristics of simplicity and convenience in synthesis, high delivery efficiency and good biological safety, and has a good application prospect.

BIFUNCTIONAL COMPOSITE MOLECULE OF ANTI-TUMOR ANTIBODY AND INTERLEUKIN-15 PRECURSOR, AND USE OF BIFUNCTIONAL COMPOSITE MOLECULE

Resumen de: EP4818212A1

0001 The present inventions provides a complex molecule, a nucleic acid, a vector, a host cell, and a pharmaceutical composition, and use thereof in the manufacture of a medicament for treating cancer. The complex molecule comprises an antitumor antibody domain, a linker, and pro-IL-15, wherein the antitumor antibody domain and pro-IL-15 are linked by the linker. The antitumor antibody domain is a complete antibody, a nanobody, or an antigen-binding fragment thereof against an immune checkpoint molecule, a tumor antigen molecule, or an immune activation molecule. The linker is a polypeptide linker or a non-peptide linker. The pro-IL-15 is a fusion protein comprising IL-15, an IL-15Rα sushi domain, a linking peptide, and optionally an IL-15Rβ extracellular domain, wherein the IL-15Rβ extracellular domain, IL-15, and the IL-15Rα sushi domain are linked by linking peptides.

COMPOUND COMPRISING EXTRACELLULAR VESICLES DERIVED FROM BIOLOGICAL MATERIAL NOT BELONGING TO THE ANIMAL KINGDOM AND ITS APPLICATIONS

Resumen de: WO2025114909A1

Compound for relieving inflammation in an organism comprising nanometer-sized extracellular vesicles (EVs) derived from biological material not belonging to the animal kingdom, but preferably belonging to the plant and fungi kingdoms, and loaded with a bioactive or a mixture of bioactives, preferably of plant origin.

CANNABIS COMPOSITIONS, ORAL PRODUCTS, AND METHODS OF MAKING SAME

Resumen de: US12263241B1

The disclosed technology includes cannabinoid oral products, and methods for making same. In some embodiments, the oral products are pouches including cannabinoid infused wafers. In some embodiments, the method of making the cannabinoid oral products includes preparing an emulsion, preparing a spray dry solution, spray drying solution into cannabinoid and carbohydrate particles, preparing a paste, preparing a wafer in a heated vacuum oven, fragmenting the wafer into cannabinoid infused wafer fragments, mixing the cannabinoid infused wafer fragments with starch, and dispensing the cannabinoid infused wafer fragments into pouches. The methods may also include labeling the oral products, for example, with a THC warning symbol.

Dithranol-containing composition

Resumen de: GB2705252A

A composition is disclosed for topical application comprising dithranol, silicon nanoparticles, one or more phospholipids and water, wherein the dithranol is present in an amount of at least 0.5 wt% by weight of the composition, the silicon nanoparticles comprise at least 50 wt% silicon and where the silicon nanoparticles and the one or more phospholipids are present in a combined weight ratio with respect to the dithranol of less than 30:1. The composition finds use in the treatment of alopecia areata. A method for the preparation of the aforementioned composition is also disclosed. The composition allows the controlled release of dithranol upon application to the skin and protects it from oxidative degradation. No figure to publish

点眼投与により乾燥型黄斑変性症および網膜光障害を予防・治療するための眼科用製剤

Resumen de: WO2022156371A1

A carrier or auxiliary material of an ophthalmic preparation, a preparation method therefor, and an application thereof, relating to the field of ophthalmic drug delivery. The carrier or auxiliary material of the ophthalmic preparation contains components such as a surfactant and an ionic polymer, and also contains a solvent. Or, the carrier or auxiliary material of the ophthalmic preparation contains components of low-polymerization-degree povidone and medium-polymerization-degree povidone, and also contains a solvent. Spherical nanobodies are formed in the solvent by the components contained in the carrier or auxiliary material of the ophthalmic preparation, have a particle size of 1-100 nm, and can be self-assembled to form spherical nanospheres having a particle size of 10-2000 nm. The administration carrier can wrap a drug through an anterior segment to efficiently deliver the drug to a posterior segment to play a therapeutic action, thereby achieving the purpose of treating diseases of the ocular fundus by means of eye drop administration, solving the technical problem that is always worked on but not resolved in the field of ophthalmic drug delivery, and achieving extremely excellent clinical application prospects and very positive social significance.

活性分子送達に利用可能な分解性脂質及びそのナノ粒子

Resumen de: CN117865863A

The present invention provides an ionizable lipid compound having an optimized carbon chain length and amine head, thereby having increased delivery efficiency for active molecules, including but not limited to nucleic acids, proteins, small molecule drugs, and the like; the present invention also relates to a lipid nanoparticle (LNP) comprising said ionizable lipid compound and an active molecule, and to a pharmaceutical composition comprising said lipid nanoparticle.

リン脂質薬物複合体、その調製方法および使用

Resumen de: EP4786521A1

0001 Disclosed in the present invention are a phospholipid drug conjugate and a preparation method and use therefor. Disclosed are the phospholipid drug conjugate as shown in formula (I), or a stereoisomer, prodrug, pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof. The phospholipid drug conjugate disclosed by the invention has good water solubility, can self-assemble to form a nanostructure, and has an excellent tumor inhibition effect.

眼内血管新生疾患用組成物及び眼内血管新生疾患用組み合わせ医薬

Resumen de: JP2026154719A

0001 【課題】低侵襲性で眼内血管新生疾患に対する薬効が得られる眼内血管新生疾患用組成物を提供する。 【解決手段】眼内血管新生疾患用組成物は、第１の水溶性ポリマーとフラボノイド分子とのコンジュゲート及び第２の水溶性ポリマーを含むナノ粒子を含有する。眼内血管新生疾患用組成物は、抗血管内皮成長因子薬と併用される。 【選択図】図１３

腫瘍学関連タンパク質およびペプチドの産生のための修飾ポリヌクレオチド

Resumen de: US2013259923A1

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

脂質組成物および治療剤を送達する方法

Resumen de: WO2024085190A1

It is an object of the present invention to provide a lipid composition capable of delivering a nucleic acid such as RNA to a hematopoietic stem/progenitor cell or mesenchymal stem cells, and a method of delivering a therapeutic agent to a cell using the lipid composition. The present invention provides a lipid composition comprising (A) a therapeutic agent and (B) a lipid nanoparticle conjugated to a targeting molecule, wherein the lipid nanoparticle comprises an ionizable lipid, and the targeting molecule specifically binds to a marker of hematopoietic stem / progenitor cells or mesenchymal stem cells.

ＶＥＧＦポリペプチドをコードする環状ＲＮＡ、製剤、および使用方法

Resumen de: WO2025045142A1

Disclosed herein are immunogenic compositions having circular RNAs encoding VEGF polypeptides. Related methods for manufacture and therapeutic uses thereof are also provided herein.

分解性分岐型脂質化合物、それを調製する方法、それを含む脂質ナノ粒子（ＬＮＰ）、およびそれを使用する方法

Resumen de: CN122228240A

In one aspect, the disclosure relates to ionizable lipid compounds of formula (I). In another aspect, the disclosure relates to the preparation of ionizable lipids of formula (I). In another aspect, the present disclosure relates to lipid nanoparticles (LNPs) comprising at least one ionizable lipid of formula (I) and methods of use thereof.

一种靶向tRF-Glu-TTC-009的核酸抑制剂在制备改善肿瘤免疫微环境药物中的应用

Resumen de: CN122849277A

本发明公开了一种靶向tRF‑Glu‑TTC‑009的核酸抑制剂在制备改善肿瘤免疫微环境药物中的应用，属于生物医药技术领域。本发明提供的核酸抑制剂（包括反义寡核苷酸、siRNA、shRNA或antagomir）通过特异性封闭tRF‑Glu‑TTC‑009，解除其对TAB1/IRAK4的靶向抑制，恢复NF‑κB信号活性，从而将巨噬细胞由M2样表型逆转为M1样抗肿瘤表型，并重塑肿瘤免疫微环境。对乳腺癌的临床治疗具有重要意义。

一种载有尿酸酶的自润滑纳米材料及其制备方法和应用

Resumen de: CN122849470A

本申请属于生物医用材料技术领域，具体涉及一种载有尿酸酶的自润滑纳米材料及其制备方法。所述载有尿酸酶的自润滑纳米材料包括主体材料和负载于主体材料上的药物分子；所述主体材料包括多巴胺甲基丙烯酰胺、含冠醚配位基团的可聚合丙烯酸酯类功能单体和2‑甲基丙烯基酰氧乙基磷酰胆碱。本申请所述载有尿酸酶的自润滑纳米材料将润滑材料、钠离子络合结构和尿酸酶递送功能集于同一自组装纳米颗粒体系中。相比于传统治疗方案，本申请所述材料可通过关节腔局部注射直接作用于痛风病灶区域，有利于提高局部有效浓度，减少全身给药带来的潜在副作用，并更好地适应痛风性关节炎中尿酸盐晶体沉积、炎症反应和润滑丧失并存的复杂病理环境。

ＲＮＡコンストラクトおよびその使用

Resumen de: CN113521269A

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

一种表面生长无机钙壳层的锰基金属有机框架药物载体及其制备方法和抗肿瘤应用

Resumen de: CN122849191A

本发明涉及生物材料技术领域，特别是涉及一种表面生长无机钙壳层的锰基金属有机框架药物载体及其制备方法和抗肿瘤应用。本发明利用无机钙壳层提升载体体内安全性与肿瘤靶向能力，稳定优化药物体内药代动力学特征，实现化疗药物与功能性锰离子安全长效共递送。载体富集至肿瘤微环境后，可依托酸性微环境特异性逐层降解释药，同步介导化学动力学治疗、激活机体内源抗肿瘤免疫通路，多元联动实现高效协同抑瘤。最终确立一类生物相容性佳、活体安全性高的新型肿瘤协同锰疗法。

一种仿生细菌囊泡制剂及其制备方法和应用

Resumen de: CN122849193A

本发明公开了一种仿生细菌囊泡制剂，包括表面修饰有脲酶和叶酸的细菌囊泡和负载于所述细菌囊泡中的活性成分，其中，所述活性成分为级联多酶体系或者治疗性核酸分子。本发明在双歧杆菌囊泡表面修饰脲酶结构，能够催化尿素产生NH3和CO2，NH3中和胃酸防止囊泡降解，而CO2为囊泡的运动提供了微动力。进一步，通过脂质‑叶酸偶联物修饰囊泡，赋予了细菌囊泡靶向小肠的功能。口服给药后，包封在囊泡内的β‑半乳糖苷酶、半乳糖氧化酶和过氧化氢酶发生时空耦合的级联反应，促进乳糖及其中间产物半乳糖和过氧化氢的快速降解，从而对乳糖不耐受产生良好的治疗效果。所述仿生囊泡平台还兼具递送不同mRNA的潜力，为代谢性疾病的治疗提供了一种新方案。

黄芩苷靶向纳米粒及其制备方法和用途

Resumen de: CN122849190A

本申请实施例提供了一种黄芩苷靶向纳米粒及其制备方法和用途，涉及生物医药技术领域。本申请实施例的黄芩苷靶向纳米粒包括聚乳酸‑羟基乙酸共聚物基质和脂质组合物，所述聚乳酸‑羟基乙酸共聚物基质中分散包埋有黄芩苷和油酸修饰超顺磁性四氧化三铁纳米粒；所述脂质组合物分布于聚乳酸‑羟基乙酸共聚物基质的表面；所述脂质组合物包括大豆磷脂和二硬脂酰磷脂酰乙醇胺‑聚乙二醇2000。本实施例构建的聚合物‑脂质杂合纳米粒能有效改善黄芩苷水溶性差及稳定性弱的理化缺陷，同时实现纳米粒体内长循环、高细胞摄取、磁场定向肿瘤富集多重性能，显著提升黄芩苷肿瘤靶向递送效率，进而有效改善抗肿瘤治疗效果。

一种石墨烯远红外消炎镇痛贴及其制备方法

Resumen de: CN122849004A

本发明公开了一种石墨烯远红外消炎镇痛贴及其制备方法，包括膏体和基布，膏体由膏体基质和分散于其中的功能性微囊组成；功能性微囊包含芯材和壁材，芯材为石墨烯量子点与纳米级远红外陶瓷粉的复合物，壁材为多孔聚乳酸‑羟基乙酸共聚物；膏体基质由包括如下质量份数的组分制备而成：多孔石墨烯气凝胶2~5份、功能性微囊10~25份、热熔胶60~80份、渗透促进剂2~5份、挥发油组分3~10份；多孔石墨烯气凝胶的孔径分布为50~200nm，比表面积为300~600m²/g，且其表面接枝有亲水性羧基和疏水性烷基链，形成两亲性表面结构；将多孔石墨烯气凝胶与功能性微囊复合应用于消炎镇痛贴中，作为高效的导热骨架和远红外辐射增强基体，显著提升热量在膏体层中的传导速率和分布均匀性。

吉西他滨两亲性前体药物

Resumen de: WO2019204869A1

The present invention relates to improved prodrugs, and compositions thereof. In particular, it relates to amphiphilic gemcitabine prodrugs or amphiphilic prodrugs of other biologically active molecules with the capacity to make liquid crystalline nanostructured nanoparticles, and uses thereof to treat animals, including humans.

一种肺炎支原体多价mRNA疫苗及其制备方法和应用

Resumen de: CN122849427A

本发明公开了一种肺炎支原体多价mRNA疫苗及其制备方法和应用，涉及生物医药技术领域。所述疫苗包括编码肺炎支原体抗原的mRNA分子和荷载所述mRNA分子的脂质纳米颗粒；所述肺炎支原体抗原为P1抗原片段、P30抗原片段、P116抗原片段和CARDS抗原片段及其组合；所述P1抗原片段的氨基酸序列如SEQ ID NO：1所示；所述P30抗原片段的氨基酸序列如SEQ ID NO：2所示；所述P116抗原片段的氨基酸序列如SEQ ID NO：3所示；所述CARDS抗原片段的氨基酸序列如SEQ ID NO：4所示。本发明采用非核苷酸修饰的mRNA技术路线，通过序列优化和低dsRNA副产物T7 RNA聚合酶突变体合成策略，在实现高效翻译表达的同时，避免了非预期移码错译蛋白的产生和潜在的脱靶免疫应答，使疫苗更加安全可靠。

一种负载TRPA1抑制剂的靶向声动力纳米药物及其制备方法

Resumen de: CN122849441A

本发明属于生物医药技术领域，提供了一种负载TRPA1抑制剂的靶向声动力纳米药物及其制备方法。将氯化铁、苯甲酸和TCPP、TRPA1抑制剂混合后反应制备中间体，然后负载GOx并包裹透明质酸获得纳米材料。上述纳米材料可用于治疗过表达CD44受体并且存在TRPA1离子通道介导的钙稳态紊乱或迁移侵袭特征的实体瘤。本发明提供的方法步骤简单、可重复性强，且制备的纳米材料具有良好的生物相容性和安全性。本发明构建的纳米材料将声动力疗法、肿瘤饥饿疗法、铁死亡和离子通道干预有机结合，实现了多重机制的协同增效。在4T1‑Luc原位乳腺癌模型中，该材料联合超声展现出显著的肿瘤生长抑制、肺转移减少的效果。

一种仿生型唑类可电离脂质化合物及其制备方法和应用

Resumen de: CN122854130A

本发明涉及一种仿生型唑类可电离脂质化合物及其制备方法和应用，仿生型唑类可电离脂质化合物结构仿天然磷脂设计，在咪唑环或噻唑环的4位与5位上分别修饰有1,2‑二酰甘油酯，并在咪唑环或噻唑环2位上修饰有不同烷基链长的含氮基团，形成具备四条柔性脂链的四酰基唑类仿生脂质。仿生型唑类可电离脂质化合物与治疗性药物及其他脂质辅料混合，能够制备得到治疗性药物被装载在内的载药脂质纳米颗粒，作为药物递送系统用于脑靶向药物的制备；仿生型唑类可电离脂质化合物具备调控血脑屏障开放‑闭合的功能，能够实现血脑屏障可逆开放；所形成的药物递送系统能够穿越血脑屏障并较好地实现所装载治疗性药物的脑靶向递送。

一种分阶段实现溶酶体规避与靶向的载药脑部递送载体及其应用

Nº publicación: CN122849186A 02/10/2026

Solicitante:

湖北大学

Resumen de: CN122849186A

本发明公开了一种分阶段实现溶酶体规避与靶向的载药脑部递送载体，其以叶酸修饰的聚合物纳米材料为载药内核，以膜融合脂质体与人脑微血管内皮细胞膜融合形成的仿生杂化膜为包覆层。该载药脑部递送载体跨越血脑屏障时，可通过膜融合机制规避传统溶酶体胞内转运途径，有效避免药物载体在脑微血管内皮细胞内发生溶酶体滞留与降解，保障载药内核高效穿透脑部血管抵达脑实质；随后，载药内核可借助表面特异性配体叶酸精准靶向脑肿瘤细胞，并于其溶酶体内释放药物，一方面有效削弱肿瘤细胞溶酶体的细胞保护效应，另一方面可直接破坏肿瘤细胞溶酶体，引发其功能紊乱和内容物外泄，诱导肿瘤细胞死亡，从多维度显著提升脑肿瘤治疗效果。